Navigation Links
Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action

eat serious diseases where there is a need for safer and/or more efficacious therapies. Othera has already identified potential lead molecules for its initial disease targets: cancer-associated thrombosis, tumor resistance to chemotherapy (chemoresistance) and rheumatoid arthritis.

Thrombosis associated with cancer remains one of the leading complications leading to death among cancer patients, and select OT-300 compounds could represent a treatment. Dr. Mousa will present data on one or more compounds from the OT-300 Program at the ISTH meeting. Othera intends to complete pre-clinical work in the coming months to support corporate partnering activity for further development of these compounds.

About Othera Pharmaceuticals

Othera Pharmaceuticals, Inc. is a privately-held, specialty pharmaceutical company located in Exton, PA. Othera is designing and developing small molecule products with novel mechanisms of action for ophthalmic and other indications. In ophthalmics, we are developing topical eye drop products for age-related diseases, including some of the leading causes of blindness. Othera is also engaged in the discovery of a novel set of orally-administered compounds to address severe medical conditions including cancer and chronic inflammatory diseases.

Othera's lead compound, OT-551, is an eye drop currently in Phase 2 clinical development. OT-551 has application to several major eye diseases and conditions, including the dry and wet forms of age-related macular degeneration (AMD), cataracts, and dry eye syndrome. Othera's second lead compound, OT-730, is a novel improved beta-blocker in preclinical development for the treatment of glaucoma. More information on Othera Pharmaceuticals is available on the company's website at www.othera.com.

Contact

Othera Pharmaceuticals, Inc., Exton
by
FD Life Sciences
Matt Dallas, 212-850-5627
matt.dallas@f
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:8/19/2008)...EGO, Aug. 19 /- Vical Incor...h collaboration with the Karolinska,Institute, a l...h Institute,for Infectious Disease Control (SMI), ...Vaxfectin(R) adjuvant with the Biojector(R) 2000,n...ologies Inc.,OTCBB:BJCT) for a multivalent preven...
(Date:8/18/2008)...findings offer hope for increased life expectancy ...8 /PRNewswire-USNewswire/ -- In the world of Down,... progress has been,tracked for the past 16 years, ... life expectancy of a person with Down syndrome, c...n ,Mr. C, was born. Further, ,Mr. C, does,not exhi...
(Date:8/18/2008)... - Clinical trial currently in Phase I -, .../ -- Tobira,Therapeutics Inc., a clinical stage bi...product discovery against life-threatening and lif...e issuance of Patent No. 7,371,772,B2 by the U.S. ...BR-652, a,CCR5 antagonist currently in Phase I dev...
(Date:8/14/2008)...ORE, Aug. 15 /- AstraZeneca...artnership with the National Cancer,Centre Singapo...H) to,develop anti-cancer compounds. The collabora...tanding (MOU) that was signed today, aims to furth...es in Asia and ultimately,speed up access to new m...
Breaking Medicine Technology:Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 2Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 4Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 5Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 2Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 2AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 5AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 6Software Techniques Inc Selects M2SYS Fingerprint Software to Meet Continuous Growth and Demand for Desktop Biometric Time 26 Attendance Solutions 1357 1Software Techniques Inc Selects M2SYS Fingerprint Software to Meet Continuous Growth and Demand for Desktop Biometric Time 26 Attendance Solutions 1357 2High Q NIST nanowires may be practical oscillators 1973 1High Q NIST nanowires may be practical oscillators 1973 2Will Rogers Institute to Honor Worlds Leading Geneticist and Recent Medal of Freedom Recipient Dr Francis S Collins For His Outstanding Contributio 7061 1Will Rogers Institute to Honor Worlds Leading Geneticist and Recent Medal of Freedom Recipient Dr Francis S Collins For His Outstanding Contributio 7061 2Viramontes to Lead PPD Clinical Operations in Mexico Central America and the Caribbean 1971 1Viramontes to Lead PPD Clinical Operations in Mexico Central America and the Caribbean 1971 2Viramontes to Lead PPD Clinical Operations in Mexico Central America and the Caribbean 1971 3
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
... has offered invaluable advice to women of childbe...ultivitamin daily, to cut the risks of delivering ...has indicated that by being regular with intake of...ny severe birth defects can be offset. The defects...
...dents are unprepared for skilled prescribing, warn...ribing in the UK is abundant, write Jeffrey Aronso... underprescribed and prescription errors are commo...ork in hospitals. The reasons for these errors a...
...etes in pregnancy has increased four times among A...cerns that gestational diabetes// may cause proble...ent in the last five years. Diabetes Australia NSW...a dangerous precedent. "In just five years we hav...
...University of South Florida College of Medicine sa... Florida is discouraging medical students// from o...alization. The situation means that many people do...Deutsch, MD, lead author of the study and chief re...
Other Medicine News:Health News:Many Medical Students Unprepared for Skilled Prescribing 2Health News:Malpractice Worry Discouraging Medical Students From Taking Up Obstetrics And Gynecology 2
Inquire
...yles. Each style has multiple sizes. Style 1 is by... available non-sterile and sterile, and are packag...s are mirror-image meaning that they are each made... normally inserted through a transaxillary (armpit...
...vivo results may be affected by the thickness of t...on scar tissue can impact the desired augment-atio...from patient to patient. Implant dimensions can be... scissors. All dimensions in centimeters. This dev...
...Qmark family elevates your ECG and Spirometry capa...ity, cost-savings and efficient patient care. The ...in the office, clinics and medical centers as well...en used in conjunction with the IQmark Digital ECG...
Medicine Products: